Compare Cassava Sciences Inc (FLNA) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Royal Caribbean Cruises Ltd — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Royal Caribbean Cruises Ltd trades at $292.23 (market cap $78.36B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 1474.6× Cassava Sciences Inc's market cap, and Royal Caribbean Cruises Ltd pays a 1.71% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | RCL | |
|---|---|---|
Market Cap | $53.14M | $78.36B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $365.84 |
52-Week Low | $1.09 | $246.71 |
Enterprise Value | -$33.43M | $99.64B |
Dividend Yield | — | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Royal Caribbean (RCL) trades at $283.09, down 1.91% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. Fundamentally, the company demonstrates strong profitability with 24.36% net margins and 50.41% ROE, supported by consistent revenue growth from $8.8B in 2022 to $17.9B in 2025. Recent earnings show mixed results with Q1 2026 beating expectations while Q4 2025 missed.
The stock offers 16% upside to the consensus price target of $328, with analysts maintaining a buy-heavy stance (48% buy ratings). Key risks include Europe weakness offset by Caribbean strength, high debt levels, and competitive pressures. Cash flow trends show improving operational performance with $6.5B operating cash flow in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
